Amgen Inc.

AMGN

US0311621009

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 10:33:16 2026-02-10 am EST			5-day change	1st Jan Change
368.57 ^USD	-1.93%		+9.25%	+13.02%

10:07am	Mizuho Raises Price Target on Amgen to $295 From $280, Keeps Outperform Rating	MT
07:03am	Daiwa Securities Adjusts Price Target on Amgen to $410 From $370, Maintains Outperform Rating	MT

Amgen: "Large majority" of people in 52-week Maritide extension study given lower monthly dose or quarterly dose of drug maintained weight loss achieved in part 1 of phase 2 trial

Published on 01/12/2026 at 06:54 pm EST

Reuters

Latest news about Amgen Inc.

10:07am	Mizuho Raises Price Target on Amgen to $295 From $280, Keeps Outperform Rating	MT
07:03am	Daiwa Securities Adjusts Price Target on Amgen to $410 From $370, Maintains Outperform Rating	MT
Feb. 06	Guggenheim Adjusts Price Target on Amgen to $347 From $305, Maintains Neutral Rating	MT
Feb. 06	Argus Research Adjusts Price Target on Amgen to $400 From $360, Maintains Buy Rating	MT
Feb. 05	CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5)	RE
Feb. 05	Deutsche Bank Adjusts Amgen Price Target to $295 From $285, Maintains Hold Rating	MT
Feb. 04	Health Care Up After Eli Lilly Earnings -- Health Care Roundup	DJ
Feb. 04	Sector Update: Health Care Stocks Rise Late Afternoon	MT
Feb. 04	Amgen Seen Driving Long-Term Growth on R&D Pipeline, Oppenheimer Says	MT
Feb. 04	Novo Nordisk exposed to a price war over obesity treatments
Feb. 04	Novo Nordisk risks weight-loss price war as discount pressures deepen	RE
Feb. 04	TD Cowen Adjusts Price Target on Amgen to $420 From $389, Maintains Buy Rating	MT
Feb. 04	Leerink Partners Adjusts Price Target on Amgen to $355 From $305, Maintains Market Perform Rating	MT
Feb. 04	Citigroup Adjusts Price Target on Amgen to $345 From $315, Maintains Neutral Rating	MT
Feb. 04	Cantor Fitzgerald Adjusts Price Target on Amgen to $350 From $315, Maintains Neutral Rating	MT
Feb. 04	Novo Nordisk risks weight-loss price war as discount pressures deepen	RE
Feb. 04	Health Rounds: Cancer immunotherapies may be more effective given earlier in the day	RE
Feb. 04	RBC Raises Price Target on Amgen to $360 From $335, Keeps Outperform Rating	MT
Feb. 04	Morgan Stanley Raises Price Target on Amgen to $309 From $304, Keeps Equalweight Rating	MT
Feb. 04	Goldman Sachs Adjusts Price Target on Amgen to $415 From $403, Maintains Buy Rating	MT
Feb. 03	Amgen posts Q4 total revenue $9.87 bln vs IBES estimate $9.47 bln	RE
Feb. 03	Amgen Inc., Q4 2025 Earnings Call, Feb 03, 2026
Feb. 03	Pyxis Oncology, Inc. Announces Chief Executive Officer Changes, Effective February 3, 2026	CI
Feb. 03	Amgen Logs Higher 4Q Revenue on Double-Digit Volume Boost	DJ
Feb. 03	Amgen Q4 Adjusted Earnings Fall, Revenue Rises; Issues Guidance	MT

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.4% of net sales.

Employees

28,000

Sector

Pharmaceuticals

Calendar

Feb. 12 -

More about the company